Clinical adverse reactions and treatment strategies of tumor immune checkpoint blockades

Tingting Wang, Qin Luo, Xiangliang Yuan, Lisong Shen

Research output: Contribution to journalReview articlepeer-review

Abstract

As representatives of immune checkpoint blockades (ICBs), antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) have significantly improved the treatment efficacies of a variety of malignant tumors. However, ICBs can also produce a wide range of immune-related adverse reactions, forcing patients to stop treatment and even affect the survival of the patients. Therefore, with the wide application of ICBs in clinical practice, clinical oncologists need to fully understand the possible side effects of ICBs therapy and the appropriate treatment strategies to improve the survival rate and therapeutic effect of patients receiving ICBs.

Original languageEnglish (US)
Pages (from-to)164-172
Number of pages9
JournalTumor
Volume38
Issue number2
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Keywords

  • Antineoplastic protocols
  • Cytotoxic T lymphocyte-associated antigen-4
  • Drug-related side effects and adverse reactions
  • Immune checkpoint programmed death-1
  • Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical adverse reactions and treatment strategies of tumor immune checkpoint blockades'. Together they form a unique fingerprint.

Cite this